James Basta

CIK: 0001792726

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NTLA

Intellia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

NTLA
Intellia Therapeutics, Inc.
Mar 2, 2026
Sale(S)
Direct
1.2K shares at avg. $13.78$17K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2026
Award(A)
Direct
46.1K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
10.4K shares at avg. $9.21$96K
NTLA
Intellia Therapeutics, Inc.
Mar 4, 2025
Sale(S)
Direct
2.6K shares at avg. $8.99$23K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
40K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
7.1K shares at avg. $12.18$86K

		Type	Shares	Price		Ownership
Mar 2, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	1,211	$13.78	$16,688	Direct
Mar 1, 2026	NTLA Intellia Therapeutics, Inc.	Award(A)	46,080	-	$0	Direct
Jan 5, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	10,397	$9.21	$95,756	Direct
Mar 4, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	2,572	$8.99	$23,122	Direct
Mar 1, 2025	NTLA Intellia Therapeutics, Inc.	Award(A)	40,000	-	-	Direct
Jan 3, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	7,074	$12.18	$86,161	Direct

1-6 of 6 transactions

About BASTA JAMES

BASTA JAMES (SEC CIK 0001792726) files insider reports with the SEC as EVP, General Counsel of Intellia Therapeutics, Inc. (NTLA).

Signal8 holds 4 ownership filings by BASTA JAMES, all Form 4s, filed between Jan 7, 2025 and Mar 3, 2026. Those filings report 6 transactions, from Jan 3, 2025 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BASTA JAMES's filings is in CAMBRIDGE, MA.

Recent filings by BASTA JAMES

Mar 2, 2026: Open-market sale of NTLA shares (Form 4, code S).
Mar 1, 2026: Grant or award of NTLA shares (Form 4, code A).
Jan 5, 2026: Open-market sale of NTLA shares (Form 4, code S).
Mar 4, 2025: Open-market sale of NTLA shares (Form 4, code S).
Mar 1, 2025: Grant or award of NTLA shares (Form 4, code A).

Other insiders filing for Intellia Therapeutics, Inc. (NTLA)

Marantz Jing L., EVP, Chief Medical Officer
Dube Michael P, VP, Chief Accounting Officer
LEONARD JOHN M, President and CEO
Dulac Edward J III, EVP, Chief Financial Officer
Verwiel Frank, Director
Keresty Georgia, Director

How to read Form 4 transaction codes